The Prevalence and Pattern of *Acinetobacter* Antibiotic Resistance in the Patients Admitted to Imam Reza Hospital in Kermanshah, Iran (2016 - 2018)

Marya Shirvani1, Mohammad Hossein Zamanian1, Alireza Janbakhsh2, Babak Sayad2, Siavash Vaziri1, Zeinab Mohseni Afshar1, Ronak Miladi1, Sedigheh Khazaei1, Feizollah Mansouri3, Mandana Afsharian1 and Mitra Tarlan1, *

1Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
2Corresponding author: Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran. Email: mittn678@yahoo.com

Received 2020 October 07; Revised 2020 November 17; Accepted 2020 December 08.

Abstract

**Background:** *Acinetobacter* is a gram-negative coccobacillus, which is widespread in nature and causes several nosocomial infections, such as pneumonia, meningitis, endocarditis, skin and soft tissue infections, conjunctivitis, and bacteremia. *Acinetobacter* has also demonstrated resistance against multiple antimicrobial agents.

**Objectives:** The present study aimed to investigate the antibiotic resistance pattern of the isolated *Acinetobacter* strains from the patients admitted to various wards of Imam Reza hospital in Kermanshah, Iran.

**Methods:** This descriptive, cross-sectional study was performed on 726 patients with positive *Acinetobacter* cultures at Imam Reza hospital during 2016 - 2018. Bacterial isolates were identified using laboratory tests and based on the CLSI protocol, and the standard disc-diffusion method was used assess antibiotic susceptibility. Data analysis was performed in SPSS version 20.

**Results:** Most of the *Acinetobacter*-positive cases were isolated from the intensive care units (75.88%) and sputum (73.3%) and urine samples (10.1%). In addition, the highest and lowest resistance rate of the isolates was observed against ceftriaxone (96.6%) and ampicillin-sulbactam (58.7%), respectively.

**Conclusions:** According to the results, the bacterial isolates were multiple-drug resistant and showed resistance to ciprofloxacin, ceftazidime, ceftriaxone, cefepime, gentamicin, imipenem, ampicillin, ampicillin-sulbactam, and amikacin. The high resistance to imipenem is rather alarming as it is considered the 'last resort' in the treatment of the infections caused by gram-negative bacteria. Therefore, monitoring programs are recommended to prevent the misuse of this drug in hospitals.

**Keywords:** Nosocomial Infection, *Acinetobacter*, Antibiotic Resistance

1. Background

*Acinetobacter* is classified among gram-negative, immobile coccobacilli, which is encapsulated, forced aerobic, spore-free, and unable to ferment glucose. This bacterium is commonly found in soil and water (1, 2). It is an opportunistic pathogen that does not cause disease in healthy individuals, while it is easily transmitted through the population, urging hospitals to improve their methods of infection control. As a nosocomial pathogen, *Acinetobacter baumannii* mainly affects the patients admitted to the intensive care unit (ICU), such as patients with trauma, injuries, and burns and those requiring mechanical ventilation (3).

Resistance mechanisms may vary in different species of *Acinetobacter*. One of these mechanisms is the production of beta-lactamase enzymes, which are inactivated by the hydrolysis of the central nucleus in beta-lactam antibiotics. There are several types of beta-lactamases, including sulfhydryl variable, pseudomonas extended resistant, cefotaximase, temepicar, and AmpC beta-lactamase. In general, the genes encoding these enzymes are located on the plasmid. Other classes of beta-lactamases have emerged with the increasing use of antibiotics (e.g., cephalosporins), which are known as extended-spectrum beta-lactamases (ESBLs) and have a wider spectrum of activity compared to primary beta-lactamases. These enzymes could hydrolyze antibiotics such as penicillin, cephalosporins, and aztreonam (4, 5).
**Acinetobacter** also contain carbapenem-hydrolyzing oxacillinase enzymes, which make bacteria resistant to carbapenems and penicillins (6). In 2011, a report suggested that various genes encoding resistance against different drugs were identified in **Acinetobacter**, including beta-lactams, tetracyclines, and glycopeptides (7, 8). **Acinetobacter** species demonstrated different behaviors in terms of antibiotic resistance. In addition, the inherent resistance of the bacterium to numerous common antibiotics helps this opportunistic pathogen quickly acquire other resistance mechanisms in response to broad-spectrum antibiotics.

Antibiotic resistance assessment provides physicians with beneficial data for the selection of effective experimental treatments. Therefore, it is essential to identify resistant bacterial strains in a specific geographical region to prevent their spread.

### 2. Objectives

The present study aimed to investigate the antibiotic resistance pattern of the isolated **Acinetobacter** strains from the patients admitted to various wards of Imam Reza hospital in Kermanshah, Iran.

### 3. Methods

In this descriptive, cross-sectional study, a laboratory expert provided the list of the patients admitted to Imam Reza hospital in Kermanshah, Iran during 2016-2018 who had positive culture samples of **Acinetobacter** (sputum, urine, blood, wound, fecal, stomach, and eye samples). The susceptibility pattern and antibiotic resistance of the pseudomonas isolated from each patient were reported, and the samples were sent to the microbiology laboratory, grown in eosin methylene blue and blood agar, and incubated at the temperature of 37 °C for 24 hours. After colony growth and the initial identification of the organism, the bacterium was identified based on the colony color, presence/absence of hemolysis, and gram-smear staining prepared from the colonies.

At the next stage, antibiogram was performed using the disc-diffusion method, and the exact diameter of the growth inhibition zone was determined in millimeters using the Müller-Hinton agar medium. In addition, comparison was performed with the Clinical and Laboratory Standard Institute (CLSI) standard table for gentamicin (10 µg), ciprofloxacin (5 µg), ceftazidime (30 µg), cotrimoxazole (1.25 µg), ceftriaxone (30 µg), cefepime, imipenem, ampicillin (10 µg), ampicillin-sulbactam (10 µg), amikacin (30 µg), cefixime (5 µg), and tazobactam (110 µg).

The bacterial suspension was prepared with turbidity equivalent to 0.5 McFarland of the tube turbidity (× 108 CFU/mL 1.5), and the lawn culture was performed in triplicate using a sterile swab on a plate containing the Müller-Hinton medium. In addition, pliers were utilized to remove the discs from the freezer one hour before they were placed on the culture medium and stabilized with the tip of a pair of pliers; afterwards, the plates were incubated at the temperature of 37 °C for 24 hours. To read the results, the diameter of the inhibition zone was measured in millimeters using an accurate ruler, and the results were reported as sensitivity (S1), resistance (R2), and semi-sensitive zones (I3).

In this research, all cases of ethics in research and ethical requirements have been respected and the confidentiality of information has been preserved.

### 3.1. Statistical Analysis

Data analysis was performed in SPSS version 18 using descriptive statistics (mean, standard deviation, frequency, and percentage). In addition, chi-square (χ²) and independent t-test were applied to evaluate the correlations between antibiotic resistance, infection prevalence, and infection severity. In all the statistical analyses, P-value of 0.05 was considered significant.

### 4. Results

In 2016, 2017, and 2018, a total of 231, 271, and 224 positive cases of **Acinetobacter** were reported in the patients admitted to Imam Reza hospital, respectively. Out of 726 patients with **Acinetobacter** positive cultures during these periods, 58.1% were male, and 47.1% were female with the mean age of 60.57 ± 20.99 years.

Among the positive culture samples, 73.3% were sputum samples, 10.1% were urine samples, 6.6% were blood samples, 5.1% were wound samples, 4.7% were fecal samples, and 0.1% were stomach and eye samples. **Table 1** shows the number of the positive **Acinetobacter** cases by hospital sections. The antibiogram results are also shown in **Table 2** and **Figure 1**. According to the findings, the organism was resistant to all the antibiotics, with the highest sensitivity rate observed against ampicillin-sulbactam (27.7%).

**Figure 1.** **Acinetobacter** resistance to various antibiotics in Imam Reza hospital (2016 - 2018)
5. Discussion

The multiple-drug resistance of *A. baumannii* has led to numerous medical issues in patient treatment. The bacterial infection is associated with variable susceptibility to different antibiotics and is influenced by environmental causes and complex patterns of antibacterial use. The development and spread of resistant bacterial species in different hospital wards may have been caused by various patterns of antibiotic use and lack of sufficient resources to control hospital infections (9, 10).

In the present study, most of the samples were isolated from sputum and trachea, indicating that the respiratory tract is most commonly affected by the infections caused by *Acinetobacter*. Therefore, the infection could be controlled and prevented by the disinfection and sterilization of respiratory equipment and instruments (e.g., respiratory catheters). Our findings also indicated that the *Acinetobacter* strains that were isolated from hospitalized patients were resistant to the antibiotics that are widely used. Furthermore, some of the bacterial strains were immune to many antibiotics tested simultaneously, and the treatment of the infections caused by these organisms is extremely challenging.

The infections caused by *A. baumannii* have become more complex with the increased resistance of infection-causing strains to several antibiotics. Due to the excessive use of third-generation cephalosporins and no observance of hygienic principles in the community, which were also highlighted by our findings, considerable resistance has been reported against third-generation cephalosporins. Given the estimated 96.6% resistance to ceftriaxone and 90.8% resistance to ceftazidime, it could be inferred that third-generation cephalosporins are not effective in the treatment of the infections caused by *A. baumannii*.

In the current research, elevated carbapenem resistance (imipenem) demonstrated the indiscriminate use of these drugs regardless of the risks associated with medication resistance. In recent decades, carbapenem-resistant bacterial strains have been a monumental challenge in the ICU treatment of *Acinetobacter* infections. In this regard, Dent et al. reported that resistance of *Acinetobacter* strains to imipenem was observed in 29% and 41% of the isolates, which were resistant to aminoglycosides, cephalosporins, broad-spectrum penicillins, and quinolones (11).

In the current research, the rate of antibiotic resistance was higher due to the excessive use of imipenem in multiple hospital wards, as well as the indiscriminate and inappropriate drug usage by the population. On the other
Table 2. Results of Acinetobacter Antibiogram in Positive Culture Samples (2016 - 2018)

| Antibiotic         | Sensitive (%) | Semi-sensitive (%) | Resistant (%) | No. (%) of Tested Samples on Antibiotics |
|--------------------|---------------|--------------------|---------------|------------------------------------------|
| Ciprofloxacin      | 4.5           | 2.8                | 92.7          | 536 (73.8)                               |
| Ceftazidime        | 1.8           | 7.4                | 90.8          | 542 (74.7)                               |
| Cotrimoxazole      | 3.6           | 7.1                | 89.3          | 166 (23.3)                               |
| Ceftriaxone        | 1.6           | 1.9                | 96.6          | 640 (88.2)                               |
| Cefepime           | 2.8           | 8.5                | 88.7          | 248 (34.2)                               |
| Gentamicin         | 12.9          | 9.4                | 77.7          | 556 (76.6)                               |
| Imipenem           | 4.1           | 2.8                | 93            | 603 (83.1)                               |
| Ampicillin         | 14.4          | 7.2                | 78.4          | 125 (17.2)                               |
| Ampicillin-sulbactam| 27.7          | 13.5               | 58.7          | 155 (21.3)                               |
| Amikacin           | 5.4           | 9.7                | 84.9          | 186 (25.6)                               |

**Footnotes**

Authors’ Contribution: Alireza Janbakhsh, Marya Shivani Mohammad Hossein Zamanian, Mitra Tarlan, and Sedigheh Khazaei designed and performed experiments, analyzed data and co-wrote the paper. Sedigheh Khazaei and Mitra Tarlan performed the analysis. Marya Shivani,
Ronak Miladi, Fezollah Mansouri, Babak Sayad, Mandana Afsharian, Siavash Vaziri, Zeinab Mohseni Afshar collected the data. Mitra Tarlan wrote the paper.

**Conflict of Interests:** The authors declare no conflict of interest.

**Ethical Approval:** In this research, all cases of ethics in research and ethical requirements have been respected and the confidentiality of information has been preserved.

**Funding/Support:** This study financially supported by Kermanshah University of Medical sciences (grant 3007570).

**References**

1. Abbas PS, Mardaneh J, Dehbashi S, Jasemi SS. [Profile of antimicrobial susceptibility isolated microorganisms from hospitalized patients in PICU ward and detection of methicillin-resistant Staphylococcus aureus and ESBL-producing bacteria by phenotypic methods]. Iran South Med J. 2014;17(4):547-57. Persian.

2. Zarrilli R, Giannoulis M, Tomasoni F, Triassi M, Tsakris A. Carbapenem resistance in Acinetobacter baumannii: The molecular epidemic features of an emerging problem in health care facilities. J Infect Dev Ctries. 2009;3(5):335-41. doi: 10.3855/jidc.240. [PubMed: 19759502].

3. Walsh SE, Maillard JY, Russell AD, Catrenich CE, Charbonneau DL, Bartolo RG. Development of bacterial resistance to several biocides and effects on antibiotic susceptibility. J Hosp Infect. 2003;55(2):98-107. doi: 10.1016/s0195-6701(03)00240-8. [PubMed: 14529633].

4. Koneman EW, Allen SD, Janda W, Schreckenberger P, Winn W. Diagnostic microbiology, the nonfermentative gram-negative Bacilli. Lippincott-Raven Publishers. 1997:253-260.

5. Singh S. Extended-spectrum beta-lactamases: An overview. Diagnostic Laboratory Services. 1999.

6. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43 Suppl 2:S49-56. doi: 10.1086/504477. [PubMed: 16894515].

7. Bayram Y, Parlak M, Aypak C, Bayram I. Three-year review of bacteriological profile and antibiotic burn wound isolates in Van, Turkey. Int J Med Sci. 2011;8(10):199-219. doi: 10.7550/jms.4723. [PubMed: 23289001]. [PubMed Central: PMC3534873].

8. Liu YN, Cao B, Wang H, Chen LA, She DY, Zhao TM, et al. [Adult hospital acquired pneumonia: A multicenter study on microbiology and clinical characteristics of patients from 9 Chinese cities]. Zhonghua Jie He He Hu Xi Za Zhi. 2012;35(10):739-46. Chinese. [PubMed: 23289990].

9. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9(2):148-65. doi: 10.1128/CMR.9.2.148-165.1996. [PubMed: 8964033]. [PubMed Central: PMC278888].

10. D’Arezzo S, Principe I, Capone A, Petrosillo N, Petrucca A, Visca P. Changing carbapenemase gene pattern in an epidemic multidrug-resistant Acinetobacter baumannii lineage causing multiple outbreaks in central Italy. J Antimicrob Chemother. 2011;66(1):54-61. doi: 10.1093/jac/dkq407. [PubMed: 21080891]. [PubMed Central: PMC3031335].

11. Dent LL, Marshall DR, Pratap S, Hulette RB. Multidrug resistant Acinetobacter baumannii: A descriptive study in a city hospital. J Infect Dis. 2010;200(3):496. doi: 10.1086/673343-10.106. [PubMed: 20509238]. [PubMed Central: PMC2909240].

12. Tsakris A, Ikonomidis A, Poulou M, Spanakos K, Vrizas D, Diamidous M, et al. Clusters of imipenem-resistant Acinetobacter baumannii clones producing different carbapenemases in an intensive care unit. Clin Microbiol Infect. 2008;14(6):588-94. doi: 10.1111/j.1469-0691.2008.01996.x. [PubMed: 18397334].

13. Centers for Disease Control and Prevention. Acinetobacter baumannii infections among patients at military medical facilities treating injured U.S. service members, 2002-2004. MMWR Morb Mortal Wkly Rep. 2004;53(45):1063-6. [PubMed: 15549020].

14. Ayan M, Durmaz E, Aktaş E, Durmaz B. Bacteriological, clinical and epidemiological characteristics of hospital-acquired Acinetobacter baumannii infection in a teaching hospital. J Hosp Infect. 2005;61(1):39-45. doi: 10.1016/s0195-6701(03)00076-8. [PubMed: 12767845].

15. Antonio CS, Neves PR, Medeiros M, Mamizuka EM, Elmor de Araujo MR, Lincopan N. High prevalence of carbapenem-resistant Acinetobacter baumannii: A descriptive study in a city hospital. Int J Med Sci. 2012;9(1):42-8. doi: 10.7150/ijms.4723. [PubMed: 18397334].

16. Bassetti M, Ginocchio F, Mikulski M. New treatment options against gram-negative organisms. Crit Care. 2011;15(2):215. doi: 10.1186/cc9997. [PubMed: 21457501]. [PubMed Central: PMC3294981].

17. Abbaspour S, Mardaneh J, Ahmadi K. [The survey of shigellosis frequency and determination of antibiotic resistance profile of isolated strains from infected children in Tehran]. Iran South Med J. 2014;17(7):42-8. Persian.

18. Ahmadi K, Farajzadeh Sheyk H, Mardaneh J, Modaresi F, Shoja S. [Detection of Enterobacter sakazakii in neonatal sepsis by PCR on 16s ribosomal RNA]. Iran South Med J. 2014;17(3):272-9. Persian.

19. Ahmadi K, Mardaneh J, Saadat S. [Determination antimicrobial resistance profile of Acinetobacter strains isolated from hospitalized patients in different part of Taleghani hospital (Ahvaz, Iran)]. Iran South Med J. 2014;17(4):620-8. Persian.